<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057431</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01475</org_study_id>
    <nct_id>NCT03057431</nct_id>
  </id_info>
  <brief_title>Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis</brief_title>
  <acronym>NOSTONE</acronym>
  <official_title>Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to assess the efficacy of standard and low dose HCTZ treatment in the&#xD;
      recurrence prevention of calcium-containing kidney stones. More specifically, the&#xD;
      investigators aim to assess the dose-response relationship for three different dosages of&#xD;
      HCTZ.&#xD;
&#xD;
      Study intervention: HCTZ 12.5 mg, 25 mg or 50 mg once daily per os for 24 or 36 months. In&#xD;
      addition, all patients in HCTZ treatment arms will receive state-of-the-art non-pharmacologic&#xD;
      recommendations for stone prevention according to current guidelines.&#xD;
&#xD;
      Control intervention: Placebo once daily per os for 24 to 36 months. In addition, all&#xD;
      patients in the placebo arm will receive state-of-the-art non-pharmacologic recommendations&#xD;
      for stone prevention according to current guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men&#xD;
      and 9.4% in women. Without specific treatment, 5- and 20-year recurrence rates are 40% and&#xD;
      75%, respectively. Given the high cost of medical treatments and surgical interventions as&#xD;
      well as the morbidity related to symptomatic stone disease, medical prophylaxis for stone&#xD;
      recurrence is an attractive approach.&#xD;
&#xD;
      About 80-90% of stones are composed of calcium oxalate with various admixtures of calcium&#xD;
      phosphate. Increased excretion of calcium in the urine, hypercalciuria, is the most common&#xD;
      metabolic abnormality encountered in patients with recurrent nephrolithiasis. Thiazide&#xD;
      diuretics have been the cornerstone of pharmacologic metaphylaxis for more than 40 years. The&#xD;
      effect of thiazides to reduce the risk of stone recurrence has been attributed to their&#xD;
      ability to decrease urinary calcium excretion. However, other factors, such as reduction of&#xD;
      urinary pH and urinary oxalate excretion, probably contribute to this effect. Efficacy of&#xD;
      thiazides on recurrence prevention of calcareous nephrolithiasis was tested in 11 randomized&#xD;
      controlled trials (RCTs). With the exception of two trials, thiazides significantly reduced&#xD;
      stone recurrence. Most of these trials are from the 1980's and 90's and the cumulative number&#xD;
      of patients studied is remarkably low for such a prevalent disease. Our systematic review of&#xD;
      these RCTs revealed major methodological deficiencies in all trials, including: lack of&#xD;
      double-blinding and intention-to-treat analysis, unclear allocation concealment, lack of&#xD;
      adverse event and drop out reporting and unknown baseline risk of disease severity.&#xD;
      Furthermore, high doses of thiazides were employed in all trials, in the case of the best&#xD;
      studied thiazide, hydrochlorothiazide (HCTZ), up to 100 mg daily. At such high doses, side&#xD;
      effects occur frequently. Nowadays, thiazides are widely used in the treatment of recurrent&#xD;
      nephrolithiasis and arterial hypertension, but at significantly lower doses. In the case of&#xD;
      recurrent nephrolithiasis, however, this practice is not supported by randomized evidence and&#xD;
      consequently, the investigators do not know whether the currently employed low dose thiazide&#xD;
      regimens are effective in reducing the risk for stone recurrence.&#xD;
&#xD;
      Thus, evidence for benefits and harms of thiazide diuretics in the prevention of&#xD;
      calcium-containing kidney stones in general remains unclear. In addition, the efficacy of the&#xD;
      currently employed low dose thiazide regimens to prevent stone recurrence is not known.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of stone recurrences</measure>
    <time_frame>After 3 years</time_frame>
    <description>Composite of symptomatic or radiological recurrences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatic stone recurrences</measure>
    <time_frame>After 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of radiologic stone recurrences</measure>
    <time_frame>After 3 years</time_frame>
    <description>Measured by low-dose CT</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Nephrolithiasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.5 mg hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25.0 mg hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50.0 mg hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg hydrochlorothiazide</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>12.5 mg hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25.0 mg hydrochlorothiazide</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>25.0 mg hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50.0 mg hydrochlorothiazide</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>50.0 mg hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed Consent as documented by signature&#xD;
&#xD;
          2. Age 18 years or older&#xD;
&#xD;
          3. Recurrent kidney stone disease (≥ 2 stone events within the last 10 years prior to&#xD;
             randomization)&#xD;
&#xD;
          4. Any past kidney stone containing 50% or more of calcium oxalate, calcium phosphate or&#xD;
             a mixture of both&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pharmacologic prevention for stone recurrence less than 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          2. Patients with secondary causes of recurrent calcareous nephrolithiasis including:&#xD;
&#xD;
               -  Severe eating disorders (anorexia or bulimia)&#xD;
&#xD;
               -  Chronic inflammatory bowel disease, bariatric surgery, intestinal surgery with&#xD;
                  malabsorption or chronic diarrheal status&#xD;
&#xD;
               -  Sarcoidosis&#xD;
&#xD;
               -  Primary hyperparathyroidism&#xD;
&#xD;
               -  Complete distal tubular acidosis&#xD;
&#xD;
               -  Active malignancy&#xD;
&#xD;
          3. Patients with the following medications:&#xD;
&#xD;
               -  Thiazide or loop diuretics&#xD;
&#xD;
               -  Carbonic anhydrase inhibitors (including topiramate)&#xD;
&#xD;
               -  Xanthine oxidase inhibitors (febuxostat or allopurinol)&#xD;
&#xD;
               -  Alkali, including potassium citrate or sodium bicarbonate&#xD;
&#xD;
               -  Treatment with 1,25-OH Vitamin D (calcitriol)&#xD;
&#xD;
               -  Calcium supplementation&#xD;
&#xD;
               -  Bisphosphonates&#xD;
&#xD;
               -  Denosumab&#xD;
&#xD;
               -  Teriparatide&#xD;
&#xD;
               -  Glucocorticoids&#xD;
&#xD;
          4. Obstructive uropathy, if not treated successfully&#xD;
&#xD;
          5. Urinary tract infection, if not treated successfully&#xD;
&#xD;
          6. Chronic kidney disease (defined as CKD-EPI eGFR &lt; 30 mL/min per 1,73 m2 body surface&#xD;
             area for more than 3 months)&#xD;
&#xD;
          7. Patients with a kidney transplant&#xD;
&#xD;
          8. &gt; 3 gout arthritis episodes within one year prior to randomisation or gout arthritis&#xD;
             requiring uric acid lowering therapy&#xD;
&#xD;
          9. Cystinuria at screening&#xD;
&#xD;
         10. Hypokalemia (blood potassium level &lt; 3 mmol/L) at screening&#xD;
&#xD;
         11. Hyponatremia (blood sodium level &lt; 125 mmol/L) at screening&#xD;
&#xD;
         12. Pregnant and lactating women [pregnancy test to be performed for women of&#xD;
             child-bearing potential (defined as women who are not surgically sterilized/&#xD;
             hysterectomized, and/ or who are postmenopausal for less than 12 months)]&#xD;
&#xD;
         13. Previous (within 3 months prior to randomization) or concomitant participation in&#xD;
             another interventional clinical trial&#xD;
&#xD;
         14. Inability to understand and follow the protocol&#xD;
&#xD;
         15. Known allergy to the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Fuster, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology and Hypertension, Bern University Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Bellinzona e Valli (San Giovanni)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital (Inselspital)</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux universitaires de Genève (HUG)</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano (Civico)</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney stones</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

